Phytoconstituents such as polyphenols exhibit significant therapeutic potential; however, their clinical application is often limited by poor aqueous solubility, low membrane permeability, extensive first-pass metabolism, and inadequate bioavailability. To overcome these challenges, various nanocarrier-based delivery systems—including liposomes, nanoemulsions, and polymeric nanoparticles—have been explored. Among these, phytosome technology has emerged as a promising and superior approach for phytoconstituent delivery. Phytosomes are formed through the molecular complexation of plant bio actives with phospholipids via hydrogen bonding, resulting in lipid-compatible structures that closely mimic biological membranes. This unique architecture enhances drug stability, absorption, and systemic availability, particularly for polyphenolic compounds such as ellagic acid and resveratrol. Comparative evaluation reveals that, while liposomes offer higher encapsulation of hydrophilic compounds and polymeric nanoparticles enable sustained release, these systems are associated with limitations including drug leakage, burst release, potential toxicity, and complex manufacturing processes. Nanoemulsions, although physically stable and easy to prepare, lack vesicular organization and targeted delivery capability. Overall, phytosomes provide an optimal balance of biocompatibility, formulation simplicity, and enhanced bioavailability, making them a clinically relevant and efficient delivery platform for phytoconstituents in oral, topical, and systemic applications